Engene, Inc.

13 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Sep 2028

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

2 fees due Apr 29, 2027
1 fee due Nov 12, 2027
The maintenance fee for High Concentration Chitosan-Nucleic Acid Polyplex Compositions (US 10,647,785) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 9,850,323	High Concentration Chitosan-Nucleic Acid Polyplex Compositions In force Term ends Sep 26, 2028 · High confidence	In force	Term ends Sep 26, 2028	High confidence
US 10,647,785	High Concentration Chitosan-Nucleic Acid Polyplex Compositions In force Term ends Sep 26, 2028 · High confidence	In force	Term ends Sep 26, 2028	High confidence
US 9,404,088	Chitosan-based non-viral methods for transfecting gut cells in vivo In force Term ends Apr 4, 2029 · High confidence	In force	Term ends Apr 4, 2029	High confidence
US 8,722,646	High Concentration Chitosan-Nucleic Acid Polyplex Compositions In force Term ends Aug 19, 2029 · High confidence	In force	Term ends Aug 19, 2029	High confidence
US 8,846,102	Non-Viral Compositions and Methods for Transfecting Gut Cells in Vivo In force Term ends Dec 31, 2031 · High confidence	In force	Term ends Dec 31, 2031	High confidence
US 10,456,478	Dually Derivatized Chitosan Nanoparticles and Methods of Making and Using the Same for Gene Transfer in Vivo In force Term ends Mar 15, 2033 · High confidence	In force	Term ends Mar 15, 2033	High confidence
US 11,623,011	Dually Derivatized Chitosan Nanoparticles and Methods of Making and Using the Same for Gene Transfer in Vivo In force Term ends Mar 15, 2033 · High confidence	In force	Term ends Mar 15, 2033	High confidence
US 9,623,112	Dually Derivatized Chitosan Nanoparticles and Methods of Making and Using the Same In force Term ends Apr 24, 2033 · High confidence	In force	Term ends Apr 24, 2033	High confidence
US 10,456,481	Dually Derivatized Chitosan Nanoparticles and Methods of Making and Using the Same for Gene Transfer in Vivo In force Term ends Sep 25, 2034 · High confidence	In force	Term ends Sep 25, 2034	High confidence
US 11,167,045	Dually Derivatized Chitosan Nanoparticles and Methods of Making and Using the Same for Gene Transfer in Vivo In force Term ends Sep 25, 2034 · High confidence	In force	Term ends Sep 25, 2034	High confidence

10 of 13 patents shown.

Pro members see all 13.

Pro members: see all 13 patents

Also on record, not counted in the 13: 2 lapsed for an unpaid fee · 1 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

6 pending · 2 abandoned · 3 no status recorded

List them